title: Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Lorusso
authors.forename: Scott A
authors.initials: SA
authors.lastname: Boerner
authors.forename: Sally
authors.initials: S
authors.lastname: Hunsberger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy; D000068818:Cetuximab; D017326:Clinical Trials, Phase III as Topic; D003627:Data Interpretation, Statistical; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016019:Survival Analysis; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D044004:Xanthones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D044004:Xanthones; C066668:vadimezan; D000068258:Bevacizumab; D000068818:Cetuximab